Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 9,450 |
|
|||||
| News | - | ||||||
| Day High | 1.465 | Low High |
|||||
| Day Low | 1.41 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Checkpoint Therapeutics Inc | CKPT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.005 | 0.35% | 1.44 | 09:00:30 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.42 | 1.41 | 1.465 | 1.435 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 64 | 9,450 | US$ 1.43 | US$ 13,517 | - | 1.30 - 3.62 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 09:00:49 | 5 | US$ 1.4397 | USD |
Checkpoint Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 33.64M | 23.53M | - | 103k | -51.85M | -2.20 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Checkpoint Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/01/2024 | 19:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/05/2024 | 16:00 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
| 2/02/2024 | 19:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/02/2024 | 16:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/30/2024 | 16:10 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 1/30/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/05/2024 | 16:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/18/2023 | 06:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/17/2023 | 16:02 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 11/17/2023 | 16:01 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 11/13/2023 | 16:15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/13/2023 | 16:10 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CKPT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.43 | 1.53 | 1.39 | 1.43 | 317,186 | 0.01 | 0.70% |
| 1 Month | 2.00 | 2.01 | 1.39 | 1.64 | 360,760 | -0.56 | -28.00% |
| 3 Months | 1.86 | 2.355 | 1.39 | 1.91 | 407,702 | -0.42 | -22.58% |
| 6 Months | 2.00 | 3.62 | 1.36 | 2.12 | 657,468 | -0.56 | -28.00% |
| 1 Year | 3.30 | 3.62 | 1.30 | 2.18 | 454,454 | -1.86 | -56.36% |
| 3 Years | 29.60 | 46.40 | 1.30 | 18.13 | 645,000 | -28.16 | -95.14% |
| 5 Years | 37.00 | 53.762 | 1.30 | 22.22 | 611,997 | -35.56 | -96.11% |
Checkpoint Therapeutics Description
| Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). |
